**November 11, 2026**

To

**BSE Limited,**
Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

**National Stock Exchange of India Limited,**
Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

**Scrip Code: 540679**

**Trading Symbol: HALEOSLABS**

**SUB: OUTCOME OF THE 99TH BOARD MEETING.**

**Ref: Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e. **November 11, 2026**, have inter alia considered and approved the following:

i. **Unaudited Standalone and Consolidated Financial Results** for the quarter and half year ended September 30, 2026, as reviewed and recommended by the Audit Committee.

In this regard, we are enclosing herewith a copy of the following:

- Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, along with the Limited Review Reports issued by the Statutory Auditors thereon,
- Statement of Assets and Liabilities and Cash Flow Statement.
- Disclosure of Related Party Transactions for the half year ended September 30, 2026.

ii. **In-principle approval for entering into Strategic Alliance and Collaboration Agreement with HRV Global Life Sciences Private Limited ("HRV")** for jointly pursuing opportunities in the areas of research and development, contract manufacturing, regulatory filings and commercialisation of pharmaceutical products.

The proposed transaction shall be subject to execution of definitive agreements and completion of such customary conditions and approvals, as may be applicable.

Please note that the detailed disclosure in respect of the strategic tie-up, as required under Para B of Part A of Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, shall be submitted separately upon execution of the definitive agreement.

HALEOS LABS LIMITED HYDERABAD



**Haleos Labs Limited**
(Formerly SMS Lifesciences India Limited)
Registered & Corporate **Office:** Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad - 500 096, Telangana, India.
Tel: +91-40-6628 8888 | CIN - L74930TG2006PLC050223 | info@haleoslabs.com | www.haleoslabs.com

The above information is also available on the website of the Company at www.haleoslabs.com

The meeting of the Board commenced at 12.30 pm and concluded at 02.00 pm.

**For Haleos Labs Limited**

(Formerly known as "SMS Lifesciences India Limited")

**Trupti Ranjan Mohanty**

Company Secretary

HALEOS LABS LIMITED HYDERABAD

TRUPTI RANJAN MOHANTY

Digitally signed by TRUPTI RANJAN MOHANTY
DN: c=IN, postalCode=500034, st=TELANGANA, street=8-2-310A84, F NO 401 ,V G ENCLAVE, IBRAHIMNAGAR ,HYDERABAD,500034, l=HYDERABAD, o=Personal, serialNumber=adf4c8f13ba9eec8ad5a0482a256b31958bd1bbe4f0ca2e6b8ec020c8515fbf7, pseudonym=30fa903f77894e2fb10c156300d1e762, 2.5.4.20=a0ae94b1e3bb64e6f16137ab5094cc9607b7491cc02a7dec909622271bff5767, email=CSp(SMSLIFE.IN, cn=TRUPTI RANJAN MOHANTY
Date: 2026.11.11 13:49:21 +05'30'

**HALEOS LABS LIMITED**

(Formerly known as SMS Lifesciences India Limited)

**(CIN: L74930TG2006PLC050223)**

**Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096**

**Tel:+91-40-6628 8888, Email: cs@haleoslabs.com., website: www.haleoslabs.com**

## Standalone Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2026

( Rs. In Lakhs )

| S.No | Particulars | Quarter Ended | | | Half Year Ended | | Year Ended |
|---|---|---|---|---|---|---|---|
| | | **30.09.2026** | 30.06.2026 | 30.09.2025 | **30.09.2026** | 30.09.2025 | 31.03.2026 |
| | | **(Unaudited)** | (Unaudited) | (Unaudited) | **(Unaudited)** | (Unaudited) | (Audited) |
| 1 | Revenue From Operations | **8,820.38** | 6,782.97 | 7,784.35 | **15,603.35** | 15,688.63 | 30,098.96 |
| 2 | Other Income | **16.66** | 45.61 | 43.64 | **62.27** | 144.58 | 142.11 |
| 3 | **Total Revenue** | **8,837.04** | 6,828.58 | 7,827.99 | **15,665.62** | 15,833.21 | 30,241.07 |
| 4 | **Expenses** | | | | | | |
| | (a) Cost of Materials Consumed | **4,897.36** | 3,728.42 | 4,082.51 | **8,625.78** | 7,382.44 | 14,557.49 |
| | (b) Changes in Inventories | **(474.23)** | (783.22) | (435.89) | **(1,257.45)** | 104.25 | (650.99) |
| | (c) Manufacturing Expenses | **1,475.87** | 1,190.00 | 1,458.20 | **2,665.87** | 2,861.99 | 5,571.54 |
| | (d) Employee Benefits Expense | **1,321.48** | 1,324.63 | 1,237.52 | **2,646.11** | 2,487.02 | 4,939.27 |
| | (e) Finance Cost | **209.41** | 181.33 | 150.51 | **390.75** | 323.78 | 603.42 |
| | (f) Depreciation and Amortization Expense | **300.07** | 301.25 | 268.30 | **601.32** | 531.75 | 1,066.40 |
| | (g) Other Expenses | **562.96** | 358.58 | 362.06 | **921.53** | 689.39 | 1,634.83 |
| | **Total Expenses - (a to g)** | **8,292.92** | 6,300.99 | 7,123.21 | **14,593.91** | 14,380.63 | 27,721.96 |
| 5 | **Profit Before Tax (3-4)** | **544.12** | 527.59 | 704.78 | **1,071.71** | 1,452.58 | 2,519.11 |
| 6 | **Tax Expenses** | | | | | | |
| | (1) (i) Current Tax | **80.00** | 160.00 | 200.00 | **240.00** | 425.00 | 550.00 |
| | (ii) Relating to Earlier Year | **-** | - | - | **-** | - | (17.82) |
| | (2) Deferred Tax | **32.98** | 43.81 | 7.01 | **76.79** | 14.04 | 209.25 |
| | **Total Tax Expenses** | **112.98** | 203.81 | 207.01 | **316.79** | 439.04 | 741.43 |
| 7 | **Net Profit / (Loss) for the Period / Year (5-6)** | **431.14** | **323.78** | **497.77** | **754.92** | **1,013.54** | **1,777.68** |
| 8 | **Other Compremensive Income for the Period / Year (OCI):** | | | | | | |
| | Items that will not be reclassified to profit or Loss: | | | | | | |
| | Remeasurement of post-employment benefit obligations | **2.89** | 2.76 | 1.23 | **5.65** | 2.39 | 11.02 |
| | Income Tax effect on the above | **0.84** | 0.80 | 0.36 | **1.65** | 0.70 | 3.21 |
| | | **2.05** | 1.96 | 0.87 | **4.01** | 1.69 | 7.81 |
| 9 | **Total Comprehensive Income for the period / Year (7+8)** | **433.19** | 325.74 | 498.64 | **758.93** | 1,015.23 | 1,785.49 |
| 10 | Earnings Per Equity Share of Rs.10/- each<br>Basic / Diluted (not annualised) | **14.26** | **10.71** | **16.46** | **24.97** | **33.52** | **58.80** |
| 11 | Paid-up equity share capital (Face Value of Rs.10/- each) | **302.33** | 302.33 | 302.33 | **302.33** | 302.33 | 302.33 |
| 12 | Reserves excluding Revaluation Reserve<br>as per balance sheet of previous accounting year | | | | | | 21,155.36 |

For Haleos Labs Limited

TVVSN Murthy
Managing Director
DIN: 00465198

## Standalone Un-Audited Statement of Assets and Liabilities as at 30th September, 2026

(Rs.in Lakhs)

| Sr. No. | Particulars | As at 30.09.2026 (Unaudited) | As at 31.03.2026 (Audited) |
|---|---|---|---|
| A | **ASSETS** | | |
| 1 | **Non-Current Assets** | | |
| | (a) Property, Plant and Equipment | **18,321.95** | 18,861.20 |
| | (b) Right-of-use Assets | **83.57** | 114.91 |
| | (c) Capital Work-in-Progress | **1,020.26** | 130.07 |
| | (d) Intangible Assets | **1.48** | 2.24 |
| | (e) Financial Assets: | | |
| | (i) Investments | **2,323.17** | 2,323.17 |
| | (ii) Other Financial Assets | **306.99** | 281.50 |
| | (f) Other Non-Current Assets | **622.92** | 450.20 |
| | **Sub Total :Non-Current Assets** | **22,680.34** | 22,163.29 |
| 2 | **Current Assets** | | |
| | (a) Inventories | **8,284.38** | 6,981.30 |
| | (b) Financial Assets | | |
| | (i) Trade Receivables | **6,366.22** | 5,426.43 |
| | (ii) Cash and Cash Equivalents | **69.22** | 39.89 |
| | (iii) Bank Balances (Other than (ii) above) | **118.80** | 116.09 |
| | (c) Other Current Assets | **6,854.81** | 5,454.18 |
| | (d) Current Tax Asset (Net) | **72.51** | 152.93 |
| | **Sub Total : Current Assets** | **21,765.94** | 18,170.82 |
| | **TOTAL ASSETS** | **44,446.28** | 40,334.11 |
| B | **EQUITY AND LIABILITIES** | | |
| 1 | **Equity:** | | |
| | (a) Equity Share Capital | **302.33** | 302.33 |
| | (b) Other Equity | **21,868.94** | 21,155.36 |
| | **Sub-Total -Smaremolders' funds** | **22,171.27** | 21,457.69 |
| | **Liabilities:** | | |
| 2 | **Non-Current Liabilities** | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | **4,247.06** | 3,518.19 |
| | (ii) Lease Liabilities | **33.30** | 80.97 |
| | (b) Provisions | **415.62** | 403.28 |
| | (c) Deferred Tax Liabilities (net) | **1,650.29** | 1,571.85 |
| | **Sub-Total -Non-Current Liabilities** | **6,346.27** | 5,574.29 |
| 3 | **Current Liabilities** | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | **7,137.01** | 5,792.61 |
| | (ii) Lease Liabilities | **92.69** | 87.59 |
| | (iii) Trade Payables: | | |
| | (a) Dues to Micro & Small Enterprises | **161.96** | 81.85 |
| | (b) Dues to Creditors otherthan Micro & Small Enterprises | **6,643.75** | 5,297.47 |
| | (iv) Other Financial Liabilities | **871.90** | 1,243.38 |
| | (b) Provisions | **202.36** | 184.70 |
| | (c) Other Current Liabilities | **819.07** | 614.53 |
| | **Sub-Total - Current Liabilities** | **15,928.74** | 13,302.13 |
| | **TOTAL - EQUITY AND LIABILITIES** | **44,446.28** | 40,334.11 |

For Haleos Labs Limited

TVVSN Murthy
Managing Director
DIN: 00465198

**HALEOS LABS LIMITED**

(Formerly known as SMS Lifesciences India Limited)

**Standalone Statement of Cash Flow for the Half Year Ended 30th September, 2026**

(All amounts Rupees in Lakhs, unless otherwise stated)

| | Particulars | For the Half Year ended 30th September, 2026 | For the Year ended 31st March, 2026 |
|---|---|---|---|
| A | **Cash Flow from Operating Activities** | | |
| | Profit Before Income Tax | 1,071.71 | 2,519.11 |
| | **Adjustments for:** | | |
| | Depreciation and amortisation expense | 601.32 | 1,066.40 |
| | Interest Income classified as Investing Cash Flow | (3.03) | (7.30) |
| | Allowance for Doubtful Debts | 37.03 | (39.63) |
| | Interest on Non Current Borrowings | 186.66 | 181.94 |
| | Interest on Unsecured Loans | 4.54 | - |
| | Provision for Employee Benefits | 35.65 | 19.92 |
| | Term Loan Processing Fee | 1.80 | (4.51) |
| | Loss on Sale of Assets | - | 0.12 |
| | Profit on Sale of Assets. | (2.12) | - |
| | Interest on Leased Premises | 8.60 | 23.71 |
| | | **1,942.16** | **3,759.76** |
| | **Change in Operating Assets and Liabilities** | | |
| | (Increase)/Decrease in Trade Receivables | (976.83) | 1,065.83 |
| | (Increase)/Decrease in Inventories | (1,303.08) | (922.92) |
| | Increase/(Decrease) in Trade Payables | 1,426.38 | 780.82 |
| | (Increase)/Decrease in Other Non Current Financial Assets | (25.50) | (3.17) |
| | (Increase)/Decrease in Other Non Current Asset | (172.72) | (62.48) |
| | (Increase)/Decrease in Other Current Financial Assets | - | (0.31) |
| | (Increase)/Decrease in Other Current Asset | (1,400.62) | (343.69) |
| | (Increase) Decrease in Prepaid Taxes | (9.57) | (18.33) |
| | Increase/(Decrease) in Other Current Financial Liabilities | 20.35 | (57.95) |
| | Increase/(Decrease) in Other Current Liabilities | 204.54 | 295.47 |
| | | **(2,237.05)** | **733.28** |
| | **Cash generated from Operations** | (294.89) | 4,493.04 |
| | Income Tax Paid | (150.00) | (650.00) |
| | **Net Cash Inflow from Operating Activities "A"** | **(444.89)** | **3,843.04** |
| B | **Cash flows from Investing Activities** | | |
| | Purchase for Property, Plant and Equipment | (1,327.76) | (4,924.47) |
| | Proceeds from sale of Property, Plant and Equipment | 7.95 | 4.52 |
| | Margin Money Deposits | (0.74) | (15.20) |
| | Interest Received on Margin Money Deposit | 1.05 | 7.25 |
| | **Net Cash Outflow from Investing Activities "B"** | **(1,319.50)** | **(4,927.90)** |
| C | **Cash flows from Financing Activities** | | |
| | Proceeds from Long Term Borrowings | 1,535.00 | 3,114.20 |
| | Repayment of Long Term Borrowings | (462.17) | (1,140.35) |
| | Proceeds from Short Term Borrowings | 998.64 | (575.78) |
| | Repayment of Lease Liability | (42.55) | (70.84) |
| | Interest paid | (189.85) | (197.26) |
| | Dividend paid to company's shareholders | (45.35) | (45.35) |
| | **Net Cash (Outflow) from Financing Activities "C"** | **1,793.72** | **1,084.62** |
| | **Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)** | **29.33** | **(0.24)** |
| | Cash and Cash Equivalents at the beginning of the Financial Year | 39.89 | 40.13 |
| | **Cash and Cash Equivalents at End of the Year** | **69.22** | **39.89** |

For Haleos Labs Limited
TVVSN Murthy
Managing Director
DIN: 00465198

**Notes:**

1 The above standalone Financial Results have been reviewed and recomended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 11th November, 2026.The statutory auditors of the Company have carried out limited review of Standalone financial results for the quarter and half year ended 30th September, 2026 and expressed unmodified opinion thereon.

2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

4 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

For Haleos Labs Limited

TVVSN Murthy
Managing Director
DIN: 00465198

Place: Hyderabad
Date : 11-11-2026

**SURYANARAYANA & SURESH**
Chartered Accountants

Flat # C1, Millenium House, # 8-2-601/B,
Road No. 10, Near Zaheer Nagar Cross Road,
Banjara Hills, Hyderabad - 500 034.
☎040-23386783/35164367
✉ suryanarayanasuresh@gmail.com

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

**Review Report to**
**The Board of Directors**
**Haleos Labs Limited**
**(Formerly known as SMS Lifesciences India Limited)**

We have reviewed the accompanying statement of unaudited standalone financial results of **Haleos Labs Limited** (Formerly known as **SMS Lifesciences India Limited)** ("the Company"), for the quarter and half year ended 30th September 2026 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *"Review of Interim Financial information performed by Independent Auditor of Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 11.11.2026

For Suryanarayana&Suresh.,
Chartered Accountants
Reg. No. 006631S

Nagendra Rao Vempati
Partner
M.No:227679




UDIN:26227679HDXQJY9296

**HALEOS LABS LIMITED**

**(Formerly known as SMS Lifesciences India Limited)**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Email: cs@haleoslabs.com., website: www.haleoslabs.com

**Consolidated Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2026**

( Rs. In Lakhs )

| S.No | Particulars | Quarter Ended | | | Half Year Ended | | Year Ended |
|---|---|---|---|---|---|---|---|
| | | 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Revenue From Operations | 9,138.06 | 7,294.23 | 8,136.76 | 16,546.11 | 16,387.23 | 33,379.45 |
| 2 | Other Income | 7.89 | 46.33 | 42.40 | 53.44 | 137.54 | 243.34 |
| 3 | **Total Revenue** | 9,145.95 | 7,340.56 | 8,179.16 | 16,599.55 | 16,524.77 | 33,622.79 |
| 4 | **Expenses** | | | | | | |
| | (a) Cost of Materials Consumed | 4,950.31 | 4,013.81 | 3,901.79 | 9,077.94 | 6,675.01 | 14,669.42 |
| | (b) Changes in Inventories | (867.26) | (1,368.21) | (881.39) | (2,235.47) | (208.82) | (818.45) |
| | (c) Manufacturing Expenses | 1,847.38 | 1,566.05 | 1,732.07 | 3,413.44 | 3,382.54 | 6,642.58 |
| | (d) Employee Benefits Expense | 1,771.60 | 1,754.92 | 1,622.84 | 3,526.52 | 3,252.01 | 6,538.25 |
| | (e) Finance Cost | 214.70 | 189.96 | 161.53 | 404.66 | 348.05 | 644.52 |
| | (f) Depreciation and Amortization Expense | 424.62 | 424.45 | 388.63 | 849.07 | 771.01 | 1,546.88 |
| | (g) Other Expenses | 603.75 | 415.61 | 404.44 | 1,018.57 | 753.66 | 1,879.95 |
| | **Total Expenses - (a to g)** | 8,945.10 | 6,996.59 | 7,329.91 | 16,054.73 | 14,973.46 | 31,103.15 |
| 5 | **Profit Before Tax (3-4)** | 200.85 | 343.97 | 849.25 | 544.82 | 1,551.31 | 2,519.64 |
| 6 | **Tax Expenses** | | | | | | |
| | (1) (i) Current Tax | 80.00 | 160.00 | 215.00 | 240.00 | 455.00 | 570.00 |
| | (ii) Relating to Earlier Year | - | - | - | - | - | (17.81) |
| | (2) Mat Credit Entitlement | - | - | (15.00) | - | (30.00) | (20.00) |
| | (3) Deferred Tax | (55.11) | (0.06) | 6.72 | (55.18) | 45.57 | 207.42 |
| | | 24.89 | 159.94 | 206.72 | 184.82 | 470.57 | 739.61 |
| 7 | **Net Profit / (Loss) for the Period / Year (5-6)** | 175.96 | 184.03 | 642.53 | 360.00 | 1,080.74 | 1,780.03 |
| 8 | **Other Comprehensive Income/(Loss) (OCI):** | | | | | | |
| | Items that will not be reclassified to statement of Profit & Loss | | | | | | |
| | Remeasurement of post-employment benefit obligations | 3.71 | 5.90 | 5.35 | 9.62 | 10.26 | 15.52 |
| | Income Tax effect on the above | (1.05) | (1.62) | (1.43) | (2.68) | (2.74) | (4.38) |
| | | 2.66 | 4.28 | 3.92 | 6.94 | 7.52 | 11.14 |
| 9 | **Total comprehensive Income for the period/year (7+8)** | 178.62 | 188.31 | 646.45 | 366.94 | 1,088.26 | 1,791.17 |
| 10 | **Profit for the year attributable to:** | | | | | | |
| | Equity holders of the parent | 325.52 | 264.66 | 610.26 | 590.19 | 1,025.95 | 1,731.20 |
| | Non-controlling interest | (149.56) | (80.63) | 32.27 | (230.20) | 54.79 | 48.83 |
| 11 | **Total comprehensive income for the year attributable to:** | | | | | | |
| | Equity holders of the parent | 327.16 | 268.01 | 612.96 | 595.18 | 1,031.14 | 1,738.95 |
| | Non-controlling interest | (148.54) | (79.70) | 33.49 | (228.24) | 57.12 | 52.22 |
| 12 | Earning Per Equity Share of Rs.10/- each Basic / Diluted (not annualised) | 10.77 | 8.75 | 20.19 | 19.52 | 33.93 | 57.26 |
| 13 | Paid-up equity share capital (Face Value of Rs.10/- each) | 302.33 | 302.33 | 302.33 | 302.33 | 302.33 | 302.33 |
| 14 | Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year | | | | | | 21,052.45 |

For Haleos Labs Limited

TVVSN Murthy
Managing Director
DIN: 00465198

## Consolidated Statement of Assets and Liabilities as at 30th September, 2026

(Rs.in Lakhs)

| Sr. No. | Particulars | As at 30.09.2026 (Unaudited) | As at 31.03.2026 (Audited) |
|---|---|---|---|
| A | **ASSETS** | | |
| 1 | **Non-Current Assets** | | |
| | (a) Property, Plant and Equipment | **25,858.92** | 26,654.18 |
| | (b) Right-of-use Assets | **83.57** | 114.91 |
| | (c) Capital Work-in-Progress | **3,003.35** | 1,042.21 |
| | (d) Intangible Assets | **1.99** | 2.82 |
| | (e) Financial Assets: | | |
| | (i) Investments | **3.61** | 3.61 |
| | (ii) Other Financial Assets | **376.63** | 340.62 |
| | (f) Other Non-Current Assets | **708.62** | 971.94 |
| | **Sub Total :Non-Current Assets** | **30,036.69** | 29,130.29 |
| 2 | **Current Assets** | | |
| | (a) Inventories | **10,563.15** | 7,982.42 |
| | (b) Financial Assets | | |
| | (i) Trade Receivables | **7,527.12** | 6,133.93 |
| | (ii) Cash and Cash Equivalents | **118.07** | 120.84 |
| | (iii) Bank Balances (Other than (ii) above) | **118.80** | 116.09 |
| | (c) Other Current Assets | **1,493.29** | 1,777.38 |
| | (d) Current Tax Assets (Net) | **109.86** | 179.89 |
| | **Sub Total : Current Assets** | **19,930.29** | 16,310.55 |
| | **TOTAL ASSETS** | **49,966.98** | 45,440.84 |
| B | **EQUITY AND LIABILITIES** | | |
| 1 | **Equity:** | | |
| | (a) Equity Share Capital | **302.33** | 302.33 |
| | (b) Other Equity | **21,606.19** | 21,052.45 |
| | Equty Attributable to Share Holders of the company | **21,908.52** | 21,354.78 |
| | Non Cotroling Interest | **1,370.63** | 1,600.83 |
| | **Sub-Total -Shareholders' funds** | **23,279.15** | 22,955.61 |
| | **Liabilities:** | | |
| 2 | **Non-Current Liabilities** | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | **6,021.86** | 4,995.79 |
| | (ii) Lease Liabilities | **33.30** | 80.96 |
| | (b) Provisions | **519.99** | 493.36 |
| | (c) Deferred Tax Liabilities (Net) | **1,235.55** | 1,287.37 |
| | **Sub-Total -Non-Current Liabilities** | **7,810.70** | 6,857.48 |
| 3 | **Current Liabilities** | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | **7,334.79** | 5,889.46 |
| | (ii) Lease Liabilities | **92.69** | 87.59 |
| | (iii) Trade Payables: | | |
| | (a) Trade Payables - Micro & Small Enterprises | **221.81** | 104.59 |
| | (b) Trade Payables - otherthan Micro & Small Enterprises | **7,393.79** | 6,036.02 |
| | (iv) Other Financial Liabilities | **1,385.71** | 1,707.38 |
| | (b) Provisions | **207.26** | 188.89 |
| | (c) Other Current Liabilities | **2,241.08** | 1,613.82 |
| | **Sub-Total - Current Liabilities** | **18,877.13** | 15,627.75 |
| | **TOTAL - EQUITY AND LIABILITIES** | **49,966.98** | 45,440.84 |

For Haleos Labs Limited

TVVSN Murthy
Managing Director
DIN: 00465198

## HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)
Consolidated Statement of Cash Flow for the Half Year Ended 30th September, 2026.
(All amounts Rupees in lakhs , unless otherwise stated)

| | Particulars | For the Half Year ended 30.09.2026 | For the Year ended 31.03.2026 |
|---|---|---|---|
| A | **Cash Flow from Operating Activities** | | |
| | Profit Before Income Tax | 544.82 | 2,519.64 |
| | **Adjustments for:** | | |
| | Depreciation and amortisation expense | 849.07 | 1,546.88 |
| | Interest Income classified as Investing Cash Flows | (3.03) | (7.30) |
| | Allowance for Doubtful Debts | 37.03 | (39.63) |
| | Interest on Non Current Borrowings | 189.58 | 217.84 |
| | Interest on Unsecured Loans | 4.54 | - |
| | Provision for Employee Benefits | 57.26 | 29.41 |
| | Term Loan Processing Fee | 2.07 | (3.40) |
| | Profit on Sale of Assets | 6.88 | - |
| | Loss on Sale of Assets | - | 0.12 |
| | Interest On Leased Premises | 8.60 | 23.71 |
| | | **1,696.82** | **4,287.28** |
| | **Change in Operating Assets and Liabilities** | | |
| | (Increase)/Decrease in Trade Receivables | (1,430.22) | 784.41 |
| | (Increase)/Decrease in Inventories | (2,580.73) | (1,242.64) |
| | Increase/(Decrease) in Trade Payables | 1,389.32 | 914.82 |
| | (Increase)/Decrease in Other Non Current Financial Assets | (36.01) | (14.97) |
| | (Increase)/Decrease in Other Non Current Asset | 263.31 | (584.21) |
| | (Increase)/Decrease in Other Current Financial Assets | - | (0.31) |
| | (Increase)/Decrease in Other Current Asset | (7,445.70) | (4,429.00) |
| | (Increase) Decrease in Prepaid Taxes | (19.97) | (39.32) |
| | Increase/(Decrease) in Other Current Financial Liabilities | 20.35 | (57.95) |
| | Increase/(Decrease) in Other Current Liabilities | 8,357.05 | 4,754.24 |
| | | **(1,482.60)** | **85.07** |
| | **Cash generated from Operations** | 214.22 | 4,372.35 |
| | Income Taxes Paid | (150.00) | (650.00) |
| | **Net Cash Inflow from Operating Activities "A"** | **64.22** | **3,722.35** |
| B | **Cash flows from Investing Activities** | | |
| | Purchase for Property, Plant and Equipment | (2,266.38) | (5,786.21) |
| | Proceeds from sale of Property, Plant and Equipment | 10.95 | 4.52 |
| | Margin Money Deposits | (0.74) | (15.20) |
| | Interest Received on Margin Money Deposit | 1.05 | 7.25 |
| | **Net Cash Outflow from Investing Activities "B"** | **(2,255.12)** | **(5,789.64)** |
| C | **Cash flows from Financing Activities** | | |
| | Proceeds from Long Term Borrowings | 2,029.45 | 4,591.80 |
| | Repayment of Long Term Borrowings | (559.29) | (1,528.83) |
| | Proceeds from Short Term Borrowings | 998.64 | (575.78) |
| | Repayment of Lease Liability | (42.55) | (70.84) |
| | Interest paid | (192.77) | (233.16) |
| | Dividend paid to company's shareholders | (45.35) | (45.35) |
| | **Net Cash (Outflow) from Financing Activities "C"** | **2,188.13** | **2,137.84** |
| | **Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)** | **(2.77)** | **70.55** |
| | Cash and Cash Equivalents at the beginning of the Financial Year | 120.84 | 50.29 |
| | **Cash and Cash Equivalents at End of the Year** | **118.07** | **120.84** |

For Haleos Labs Limited
TVSN Murthy
Managing Director
DIN : 00465198

**Notes:**

1 The above Consolidated Financial Results have been reviewed and recomended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 11th November, 2026. The statutory auditors of the Company have carriedout limited review of Consolidated financial results for the quarter and half year ended 30th September, 2026 and expressed unmodified opinion thereon.

2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

3 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary.

4 The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

For Haleos Labs Limited

TVVSN Murthy
Managing Director
DIN: 00465198

Place: Hyderabad
Date : 11-11-2026

**SURYANARAYANA & SURESH**
Chartered Accountants

INDIA

Flat # C1, Millenium House, # 8-2-601/B,
Road No. 10, Near Zaheer Nagar Cross Road,
Banjara Hills, Hyderabad - 500 034.
☎040-23386783/35164367
✉ suryanarayanasuresh@gmail.com

**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of
**Haleos Labs Limited**
(Formerly known as **SMS Lifesciences India Limited)**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **Haleos Labs Limited** (formerly known as **SMS Lifesciences India Limited)** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter and half year ended 30th September, 2026 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

a. M/s. Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited)
b. M/s. Mahi Drugs Private Limited


SURYANARAYANA & SURESH * Hyderabad FR.NO.006631S * Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs.829.59 Lakhs, total net loss after tax of Rs.373.91 Lakhs and total comprehensive loss of Rs.371.35 Lakhs for the Quarter ended 30 September, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad
Date: 11.11.2026

ForSuryanarayana&Suresh.,
Chartered Accountants
Reg. No.006631S




Nagendra Rao Vempati
Partner
M. No. 227679

UDIN: 26227679YFDUQA9553

**Consolidated Related Party Disclosure for the half year ended September 30. 2026**
**[Reg. 23 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015**
**Format specified under SEBI Master Circular No. HO/49/11/14(7)2025-CFD-POD2/I/3762/2026 dated January 30. 2026]**

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

| S.No | Details of the Party (listed entity / subsidiary) entering in to the transaction | | Details of the counterparty | | | Type of related party transaction | Value of the related party transaction as approved by the audit committee (Ref - Note 1) | Value of the related party transaction ratified by the audit committee | Value of transaction during reporting period | In case monies are due to either party as a result of the transaction | | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposists, advances or investments | | | Details of the loans, inter-corporate deposits, advances or investments | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Name | PAN (Ref - Note 3) | Name | PAN (Ref - Note 3) | Relationship of the counter party with the listed entity or its subsidiary | | | | | Opening Balance | Closing Balance | Nature of indebtedness | Cost | Tenure | Nature (loans/advance/inter-corporate deposit/investment) | Interest rate (%) | Tenure | Secured/ Unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage) |
| 1 | Haleos Labs Limited (formerly known as SMS Lifesciences India Limited) | - | Purogene Labs Private Limited | - | Enterprises over which Directors or their relatives exercise significant influence | Purchases of Goods & Services | 3,000.00 | - | 881.91 | -96.88 | -218.40 | - | - | - | - | - | - | - | - |
| 2 | | | | | | Sale of Goods & Services | 1,050.00 | - | 164.12 | - | - | - | - | - | - | - | - | - | - |
| 3 | | | | | | Rent received | 10.00 | - | 2.12 | - | - | - | - | - | - | - | - | - | - |
| 4 | | | Mahi Drugs Private Limited | - | Material Subsidiary | Purchases of Goods & Services | 4,500.00 | - | 645.13 | 3,959.37 | 5,844.58 | - | - | - | - | - | - | - | - |
| 5 | | | | | | Sale of Goods & Services | 2,000.00 | - | 452.27 | - | - | - | - | - | - | - | - | - | - |
| 6 | | | | | | Rent received | 10.00 | - | 3.19 | - | - | - | - | - | - | - | - | - | - |
| 7 | | | SMS Pharmaceuticals Ltd | - | Other Related Party | Purchases of Goods & Services | 510.00 | - | 3.91 | - | - | - | - | - | - | - | - | - | - |
| 8 | | | | | | Sale of Goods & Services | 2,500.00 | - | 385.03 | 137.76 | 301.91 | - | - | - | - | - | - | - | - |
| | | | ChemWerth Inc. USA | - | Other Related Party | Purchases of Goods & Services | 500.00 | - | - | - | - | - | - | - | - | - | - | - | - |
| | | | | | | Sale of Goods & Services | 2,000.00 | - | 65.67 | -99.12 | 85.00 | - | - | - | - | - | - | - | - |
| 10 | | | TVVSN Murthy | - | Key Management Personel | Remuneration (Ref - Note 6) | - | - | 99.07 | 7.50 | 7.50 | - | - | - | 250.00 | 8.50% | Mutually Aggreed Term | Unsecured | Business Purpose |
| 11 | | | T V Praveen | - | Executive Director | | - | - | 55.91 | 5.60 | 5.34 | - | - | - | - | - | - | - | - |
| 12 | | | G Sudeepthi | - | Whole Time Director | | - | - | 14.62 | 1.61 | 1.61 | - | - | - | - | - | - | - | - |
| 13 | Mahi Drugs Private Limited | - | Purogene Labs Private Limited | - | Enterprises over which Directors or their relatives exercise significant influence | Purchases of Goods & Services | 500.00 | - | 0.16 | - | - | - | - | - | - | - | - | - | - |
| | | | | | | Sale of Goods & Services | 500.00 | - | 18.59 | - | - | - | - | - | - | - | - | - | - |
| | | | ChemWerth Inc. USA | - | Other Related Party | Purchases of Goods & Services | 500.00 | - | - | - | - | - | - | - | - | - | - | - | - |
| | | | | | | Sale of Goods & Services | 3,500.00 | - | - | -347.83 | -355.37 | - | - | - | - | - | - | - | - |
| | | | SMS Pharmaceuticals Ltd | - | Other Related Party | Purchases of Goods & Services | 35.00 | - | - | - | - | - | - | - | - | - | - | - | - |
| 16 | | | | | | Sale of Goods & Services | 510.00 | - | 24.68 | 54.60 | 24.68 | - | - | - | - | - | - | - | - |
| | | | Total | | | | | | 2,816.44 | | | | | | | | | | |

**Note:**

1. The value of the related party transactions denotes the amount approved by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of the Company and the subsidiary, *as the case may be*. for the year 2026-27.
2. Purchase / Sale of Goods & Services were approved individually by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of the Company. However, for reporting purpose the same has been clubbed.
3. As per the guidance note for disclosure of Related Party Transactions dated 25.04.2022, issued by the Stock Exchanges, since the Company is filing this disclosure in PDF format. the PAN details are not to be included in the disclosure. *(XBRL filed separately along with PAN)*
4. Aforesaid transactions with related parties are in the ordinary course of business and in arm's length basis.
5. Sitting fees paid to Independent Directors & Remuneration paid to KMPs are not disclosed pursuant to SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2021.
6. Remuneration paid to Directors were individually approved by Audit / Board / Shareholders during respective appointment / reappointment.
7. Company has extended Corporate Guarantee to Mahi Drugs during the half year ended Spet 30, 2026, related to the ECB loan of ₹20 Crores availed from RBL Bank

**For Haleos Labs Limited**

**TVVSN Murthy**
**Managing Director**
**DIN: 00465198**